MedTrace Logo

A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma

NCT02717689 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2020-06-25

No results posted yet for this study

Summary

This study explores if a composite biomarker strategy predicts exacerbation risk in patients with asthma on high dose inhaled corticosteroid (+/-long-acting beta agonist) treatment and to evaluate the utility of this composite score to facilitate personalised biomarker specific titration of corticosteroid therapy in this population.

Conditions

  • Severe Persistent Asthma

Interventions

OTHER

Biomarker based adjustment of corticosteroid dose

The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)

Sponsors & Collaborators

Principal Investigators

  • Liam Heaney, MBBCh MRCP · Queen's University, Belfast

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2019-06-19
Completion
2019-06-19

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02717689 on ClinicalTrials.gov